Eurobio Scientific Société anonyme (EPA:ALERS)
France · Delayed Price · Currency is EUR 25.25
-0.05 (-0.20%)
Sep 29, 2025, 1:43 PM CET
EPA:ALERS Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Other Revenue | 0.1 | -0 | - | - | - | - | Upgrade |
| 162.65 | 154.95 | 130.65 | 152.9 | 185.32 | 189.19 | Upgrade | |
Revenue Growth (YoY) | 12.38% | 18.60% | -14.56% | -17.50% | -2.04% | 218.10% | Upgrade |
Cost of Revenue | 86.19 | 82.99 | 73.16 | 81.66 | 85.91 | 80.68 | Upgrade |
Gross Profit | 76.45 | 71.95 | 57.49 | 71.24 | 99.41 | 108.51 | Upgrade |
Selling, General & Admin | 45.16 | 38.86 | 33.52 | 31 | 24.5 | 22.5 | Upgrade |
Research & Development | 3.85 | 4.65 | 5.91 | 3.47 | - | - | Upgrade |
Operating Expenses | 57.82 | 52.02 | 47.35 | 40.37 | 29.29 | 27.3 | Upgrade |
Operating Income | 18.63 | 19.93 | 10.14 | 30.87 | 70.12 | 81.21 | Upgrade |
Interest Expense | -4.13 | -4.13 | -4.36 | -1.26 | -0.41 | -0.6 | Upgrade |
Interest & Investment Income | 1.48 | 1.48 | 1.12 | 0.04 | - | 0 | Upgrade |
Currency Exchange Gain (Loss) | 0.69 | 0.69 | 0.75 | 0.67 | 0.36 | -0.19 | Upgrade |
Other Non Operating Income (Expenses) | -4.41 | -3.71 | 0.77 | 0.04 | -0.05 | 0.44 | Upgrade |
EBT Excluding Unusual Items | 12.26 | 14.26 | 8.42 | 30.35 | 70.01 | 80.86 | Upgrade |
Merger & Restructuring Charges | -6.6 | -6.6 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.23 | - | Upgrade |
Other Unusual Items | -1.48 | -1.38 | -1.45 | -0.67 | 1.08 | 0.03 | Upgrade |
Pretax Income | 4.18 | 6.28 | 6.98 | 29.68 | 71.31 | 80.89 | Upgrade |
Income Tax Expense | 1.79 | 2.29 | 2.14 | 4.75 | 10.77 | 7.41 | Upgrade |
Earnings From Continuing Operations | 2.4 | 4 | 4.84 | 24.94 | 60.54 | 73.48 | Upgrade |
Net Income | 2.4 | 4 | 4.84 | 24.94 | 60.54 | 73.48 | Upgrade |
Net Income to Common | 2.4 | 4 | 4.84 | 24.94 | 60.54 | 73.48 | Upgrade |
Net Income Growth | -63.90% | -17.31% | -80.61% | -58.81% | -17.61% | 2230.51% | Upgrade |
Shares Outstanding (Basic) | - | 10 | 11 | 11 | 11 | 11 | Upgrade |
Shares Outstanding (Diluted) | - | 10 | 11 | 11 | 11 | 11 | Upgrade |
Shares Change (YoY) | - | -8.49% | -1.40% | 4.59% | -3.35% | 0.10% | Upgrade |
EPS (Basic) | - | 0.39 | 0.43 | 2.20 | 5.58 | 6.56 | Upgrade |
EPS (Diluted) | - | 0.39 | 0.43 | 2.20 | 5.57 | 6.53 | Upgrade |
EPS Growth | - | -9.42% | -80.44% | -60.53% | -14.70% | 2232.14% | Upgrade |
Free Cash Flow | - | 13.45 | 22.71 | 40.24 | 64.07 | 52.63 | Upgrade |
Free Cash Flow Per Share | - | 1.31 | 2.02 | 3.54 | 5.89 | 4.68 | Upgrade |
Gross Margin | 47.01% | 46.44% | 44.00% | 46.59% | 53.64% | 57.35% | Upgrade |
Operating Margin | 11.46% | 12.86% | 7.76% | 20.19% | 37.84% | 42.93% | Upgrade |
Profit Margin | 1.47% | 2.58% | 3.70% | 16.31% | 32.67% | 38.84% | Upgrade |
Free Cash Flow Margin | - | 8.68% | 17.39% | 26.32% | 34.57% | 27.82% | Upgrade |
EBITDA | 28.24 | 29.45 | 23.29 | 40.5 | 77.98 | 88.22 | Upgrade |
EBITDA Margin | 17.36% | 19.00% | 17.82% | 26.49% | 42.08% | 46.63% | Upgrade |
D&A For EBITDA | 9.61 | 9.51 | 13.15 | 9.63 | 7.87 | 7.01 | Upgrade |
EBIT | 18.63 | 19.93 | 10.14 | 30.87 | 70.12 | 81.21 | Upgrade |
EBIT Margin | 11.46% | 12.86% | 7.76% | 20.19% | 37.84% | 42.93% | Upgrade |
Effective Tax Rate | 42.69% | 36.38% | 30.70% | 15.99% | 15.10% | 9.16% | Upgrade |
Revenue as Reported | 162.65 | 154.95 | 130.65 | 152.9 | 185.32 | 189.19 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.